CVS Health
CVS
$104.43
-0.75%
CVS Health Corporation is a diversified healthcare services company operating through retail pharmacies, pharmacy benefit management (PBM), and health insurance (Aetna) segments, serving millions of customers and members across the United States. As one of the largest integrated healthcare companies, CVS combines a retail footprint of approximately 9,000 stores, a PBM processing about 2 billion claims annually, and a top-tier insurer with roughly 27 million medical members, positioning it as a unique platform in the healthcare value chain. The current investor narrative centers on a potential turnaround, driven by a strong Q1 2026 earnings beat, a rebound in its insurance unit's medical cost ratio, and a favorable Medicare payment decision that added $13 billion in revenue visibility, fueling a significant stock rally and renewed optimism about its long-term growth prospects.…
CVS
CVS Health
$104.43
Related headlines
Investment Opinion: Should I buy CVS Today?
We rate CVS as a Buy, driven by the strong Q1 2026 earnings beat, raised guidance, and favorable regulatory tailwinds. The average analyst target of $113.50 implies ~8.7% upside, and the 'Strong Buy' consensus supports this view. The forward PE of 12.40x is attractive relative to the market, and the company's revenue growth of 6.17% YoY is solid. With a dividend yield of 3.38%, CVS offers both income and growth potential.
Sign up to view all
CVS 12-Month Price Forecast
The AI assessment is bullish, driven by the strong Q1 2026 earnings beat and the low forward valuation. The company's revenue growth is accelerating, and the regulatory environment is supportive. However, the high debt levels and thin margins warrant caution. The stance would be upgraded if the medical cost ratio continues to improve and revenue growth exceeds 7%, while a downgrade would occur if the medical cost ratio spikes or revenue growth falls below 4%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CVS Health's 12-month outlook, with a consensus price target around $113.50 and implied upside of +8.7% versus the current price.
Average Target
$113.50
0 analysts
Implied Upside
+8.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$79 - $148
Analyst target range
The target price range spans from a low of $79.00 to a high of $148.00, indicating a wide dispersion of expectations. The high target of $148 suggests some analysts see significant upside potential, likely assuming continued margin expansion and successful integration of Oak Street Health, while the low target of $79 may reflect concerns about competitive pressures or regulatory risks. Recent institutional actions have been uniformly positive, with firms like Wells Fargo, RBC Capital, and Morgan Stanley reiterating or maintaining Overweight/Buy ratings, signaling a consistent bullish sentiment among sell-side analysts.
Bulls vs Bears: CVS Investment Factors
CVS presents a compelling turnaround story with strong Q1 2026 results, accelerating revenue growth, and a favorable regulatory environment. The bull case is supported by a low forward PE and strong analyst consensus, while the bear case highlights high leverage, thin margins, and competitive threats. Currently, the bull case has stronger evidence given the recent earnings beat and raised guidance, but the key tension lies in whether the improved medical cost ratio is sustainable. If the insurance unit's profitability continues to improve, the stock could re-rate higher; if not, the high trailing PE and debt burden could weigh on shares.
Bullish
- Strong Q1 2026 earnings beat: CVS reported Q1 2026 EPS of $2.31, significantly above the prior year's $1.41, and raised its full-year guidance. This beat was driven by a lower medical cost ratio in its insurance segment, signaling improved operational efficiency and a potential turnaround.
- Revenue growth accelerating: Q1 2026 revenue grew 6.17% YoY to $100.426 billion, up from 4.9% growth in Q4 2025. This acceleration, driven by pharmacy services and premiums, indicates strong demand across its diversified business segments.
- Favorable Medicare payment decision: A CMS decision added $13 billion in revenue visibility, boosting CVS's profit outlook. This regulatory tailwind reduces uncertainty and supports long-term growth in its Medicare Advantage business.
- Low forward valuation: With a forward PE of 12.40x, CVS trades at a significant discount to the market and its own historical average. This suggests the market is pricing in an earnings recovery, offering potential upside if the turnaround materializes.
Bearish
- High trailing PE indicates past weakness: The trailing PE of 56.69x reflects depressed earnings over the past year, including a Q3 2025 loss of $3.97 billion. This highlights the volatility and uncertainty in CVS's profitability, which could persist if the turnaround stalls.
- High debt levels: CVS has a debt-to-equity ratio of 1.24, indicating significant leverage. With interest expenses around $774 million per quarter, rising rates could pressure earnings and limit financial flexibility.
- Thin net margin: Net margin is only 0.44% (TTM), reflecting the low-margin nature of its retail and PBM businesses. This leaves little room for error, as any cost overrun or pricing pressure could disproportionately impact profits.
- Competitive pressures in PBM and retail: CVS faces intense competition from Amazon in retail pharmacy and from other PBMs like Express Scripts and OptumRx. These pressures could erode market share and compress margins, limiting growth potential.
CVS Technical Analysis
CVS is in a powerful sustained uptrend, with the stock up 68.16% over the past year, dramatically outperforming the S&P 500's 18.19% gain. The current price of $104.43 sits near the top of its 52-week range, at approximately 94.4% of the distance from the low of $61.19 to the high of $110.68, indicating strong momentum and investor confidence. This positioning near the highs suggests the market is rewarding the company's improving fundamentals, though it also raises the risk of short-term overextension.
Beta
0.60
0.60x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$61-$111
Price range past year
Annual Return
+68.2%
Cumulative gain past year
| Period | CVS Return | S&P 500 |
|---|---|---|
| 1m | -0.4% | +0.3% |
| 3m | +27.2% | +4.0% |
| 6m | +40.1% | +8.3% |
| 1y | +68.2% | +20.2% |
| ytd | +30.3% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVS Fundamental Analysis
CVS's revenue trajectory is solidly growing, with Q1 2026 revenue of $100.426 billion, up 6.17% year-over-year, and a clear acceleration from the prior quarter's $105.693 billion (which was a 4.9% YoY increase). The multi-quarter trend shows consistent expansion, with revenue rising from $94.588 billion in Q1 2025 to $100.426 billion in Q1 2026, driven by strength in pharmacy services and premiums. The company's diverse revenue streams, including $56.939 billion from pharmacy revenue and $33.791 billion from premiums, provide a stable base, though the front store segment remains a smaller contributor at $5.259 billion.
Quarterly Revenue
$100.4B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
15.6%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVS Overvalued?
Given that CVS has positive net income, the PE ratio is the primary valuation metric. The trailing PE stands at 56.69x, while the forward PE is much lower at 12.40x, indicating the market expects a significant earnings rebound—consistent with the recent turnaround narrative. This wide gap between trailing and forward earnings suggests investors are pricing in a substantial recovery in profitability, which is supported by the company's raised guidance and improved medical cost ratio.
PE
56.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant, with a debt-to-equity ratio of 1.24 and quarterly interest expenses of $774 million. The company's net margin is razor-thin at 0.44%, leaving little buffer against cost inflation or pricing pressures. Additionally, the payout ratio of 192% indicates that dividends are not fully covered by earnings, which could lead to a dividend cut if profitability does not improve. The current ratio of 0.84 suggests potential liquidity concerns, as current liabilities exceed current assets, though this is common in the healthcare services industry.